Overview

* OraSure Q2 2025 revenue falls 43% yr/yr, beats analyst expectations, per LSEG data

* Adjusted operating income for Q2 beats analyst expectations, per LSEG data

* Co repurchased 1.8 mln shares during Q2

Outlook

* OraSure expects Q3 2025 revenue of $27 mln to $30 mln

Result Drivers

* COVID-19 REVENUE DECLINE - Significant drop in COVID-19 related revenues contributed to overall revenue decline

* PRODUCT PORTFOLIO EXPANSION - Launch of new blood collection device for proteomic research expected to drive future growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $31.20 $30.40

Revenue mln mln (3

Analysts

)

Q2 Gross 42.1%

Margin

Q2 Beat -$13.20 -$17.40

Adjusted mln mln (1

Operatin Analyst)

g Income

Q2 -$18 mln

Operatin

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for OraSure Technologies Inc ( OSUR ) is $6.00, about 48% above its August 4 closing price of $3.12

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)